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To the Editor,
I have read with keen interest the systematic review by Güler 
et al. (1) entitled “A review of the fi xed dose use of new oral 
anticoagulants in obese patients: Is it really enough?” published 
in Anatol J Cardiol 2015:1020-9. This review is of importance in 
everyday practice where patients with high body weights are 
encountered much more commonly than in clinical trials. The au-
thors summarized the current clinical data based on the efficacy 
and safety of non-vitamin K oral anticoagulants (NOAC) used 
in patients with atrial fibrillation (AF) and in the prevention and 
therapy of venous thromboembolism (VTE) with the emphasis on 
obesity, which is also a rapidly rising epidemic among subjects 
requiring long-term anticoagulation. The manufacturers of dabi-
gatran, rivaroxaban, and apixaban currently suggest that no dose 
adjustments are necessary for patients with high body weights 
even if the present evidence to support such a recommendation 
is rather weak (2). Although clinical trials on NOAC showed no 
weight-associated differences in the outcomes of NOAC in AF 
or VTE, several reports indicate that clinical outcomes of antico-
agulant therapy with NOAC could be unsatisfactory in extremely 
obese patients in part because of the increased clearance of 
anticoagulants and distribution volume with largely unaltered 
drug absorption (2). The authors of the current review (1) high-
lighted the intriguing concept that compared with factor Xa in-
hibitors, dabigatran, whose renal elimination is the largest (80%), 
is more prone to provide insufficient anticoagulation intensity 
in individuals with high body weights. Although no comprehen-
sive subgroup analysis for rivaroxaban or apixaban administered 
in obese patients has been published to date, the influence of 
body weight on the anticoagulant effects of these agents appear 
small. In our cohort of patients with VTE, subjects with a body 
mass index (BMI) of >35 kg/m2 represent approximately 10% pa-
tients, whereas those with BMI below 18 kg/m2 represent 5%, 
with the predominance of young women (A. Undas, unpublished 
data). From our experience, low BMI is associated with a higher 
risk of bleeding, which is a more consistent feature than simi-
lar rate of VTE recurrences in patients with BMI of >35 kg/m2 
versus those with BMI of <35 kg/m2. The choice of appropriate 
regimens of an NOAC in subjects with high body weights is dif-
ficult, particularly if the bleeding risk is increased for example in 
a form of heavy menstrual bleedings. Therefore, monitoring the 
anticoagulant effects of NOAC is important in this subset of an-
ticoagulated patients; the need for anticoagulation at high body 
weights is considered one of the well-established indications to 
determine the blood concentrations of NOAC (3, 4). However, the 
association between the blood levels of NOAC measured using 
coagulation assays and thrombotic or bleeding complication is 
uncertain because of a large variability of the results (5).
Taken together, each patient on NOAC who weighs below 50 kg 
or above 100–120 kg requires regular visits to the outpatient clinic, 
particularly within the first weeks of the therapy. The appropriate 
supervision aims to minimize the risk of bleeding or thromboem-
bolic events in particular individuals who at baseline are at a high 
risk of these complications. As suggested in the current review 
(1), more common control visits may increase the safety and ef-
ficacy of long-term anticoagulation at high body weights regard-
less of age and sex. In our opinion, laboratory monitoring of trough 
anticoagulant effects as well as creatinine clearance should be 
considered in selected patients. Further clinical studies, particu-
larly registries, are needed to determine whether a fixed dose of 
NOAC is truly efficacious in patients with morbid obesity.
Anetta Undas
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